Carlos Dzik

872 total citations
26 papers, 151 citations indexed

About

Carlos Dzik is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Carlos Dzik has authored 26 papers receiving a total of 151 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 8 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in Carlos Dzik's work include Renal cell carcinoma treatment (8 papers), Prostate Cancer Treatment and Research (6 papers) and Bladder and Urothelial Cancer Treatments (5 papers). Carlos Dzik is often cited by papers focused on Renal cell carcinoma treatment (8 papers), Prostate Cancer Treatment and Research (6 papers) and Bladder and Urothelial Cancer Treatments (5 papers). Carlos Dzik collaborates with scholars based in Brazil, United States and Germany. Carlos Dzik's co-authors include Diogo Assed Bastos, Ariel Galapo Kann, Sheila Aparecida Coelho Siqueira, Howard I. Scher, Dana E. Rathkopf, Camila Motta Venchiarutti Moniz, Suzana Mária Fleury Malheiros, Romualdo Barroso‐Sousa, Marcelo A. Queiroz and Guilherme Nader Marta and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and European Urology.

In The Last Decade

Carlos Dzik

23 papers receiving 148 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carlos Dzik Brazil 9 94 49 48 44 29 26 151
Bérengère Dadone‐Montaudié France 7 73 0.8× 39 0.8× 21 0.4× 56 1.3× 17 0.6× 23 146
Lukas Delasos United States 8 157 1.7× 64 1.3× 62 1.3× 121 2.8× 23 0.8× 20 230
Benjamin Y. Tan Singapore 10 38 0.4× 38 0.8× 93 1.9× 73 1.7× 36 1.2× 20 213
Emily S. Weg United States 6 204 2.2× 63 1.3× 107 2.2× 82 1.9× 38 1.3× 23 266
Sonja Heibl Austria 7 53 0.6× 25 0.5× 60 1.3× 103 2.3× 36 1.2× 21 155
Vasiliki Michalarea United Kingdom 7 54 0.6× 34 0.7× 30 0.6× 104 2.4× 7 0.2× 17 162
Marcelo Corassa Brazil 7 77 0.8× 51 1.0× 64 1.3× 104 2.4× 16 0.6× 19 185
Walter Lindemann Germany 5 45 0.5× 25 0.5× 71 1.5× 126 2.9× 11 0.4× 5 189
Jason Mouabbi United States 7 64 0.7× 24 0.5× 100 2.1× 113 2.6× 51 1.8× 41 205
Angad Singh India 6 41 0.4× 45 0.9× 64 1.3× 45 1.0× 6 0.2× 12 136

Countries citing papers authored by Carlos Dzik

Since Specialization
Citations

This map shows the geographic impact of Carlos Dzik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos Dzik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos Dzik more than expected).

Fields of papers citing papers by Carlos Dzik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlos Dzik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos Dzik. The network helps show where Carlos Dzik may publish in the future.

Co-authorship network of co-authors of Carlos Dzik

This figure shows the co-authorship network connecting the top 25 collaborators of Carlos Dzik. A scholar is included among the top collaborators of Carlos Dzik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos Dzik. Carlos Dzik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bastos, Diogo Assed, Carlos Dzik, Denis L. Jardim, et al.. (2025). Infiltrating Natural Killer cells influence the efficacy of BCG immunotherapy in non-muscle-invasive bladder cancer. Pathology - Research and Practice. 270. 155997–155997.
2.
Dzik, Carlos, et al.. (2023). Prostate Cancer and Spirituality: A Systematic Review. Journal of Religion and Health. 63(2). 1360–1372. 2 indexed citations
3.
Dettino, Aldo Lourenço Abbade, Ariel Galapo Kann, Carlos Dzik, et al.. (2021). Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries. JCO Global Oncology. 7(7). 545–549. 1 indexed citations
4.
Fizazi, Karim, Daniel Castellano, Arash Rezazadeh, et al.. (2021). CheckMate 9KD Arm B final analysis: Efficacy and safety of nivolumab plus docetaxel for chemotherapy-naïve metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 39(6_suppl). 12–12. 7 indexed citations
5.
Marta, Guilherme Nader, Pedro Isaacsson Velho, Sheila F. Faraj, et al.. (2020). Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell Carcinoma. Pathology & Oncology Research. 26(4). 2489–2497. 9 indexed citations
6.
Bonadio, Renata Colombo, Pedro Isaacsson Velho, Guilherme Nader Marta, et al.. (2019). Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?. ecancermedicalscience. 13. 973–973. 1 indexed citations
7.
Queiroz, Marcelo A., Felipe de Galiza Barbosa, Rafael Fernandes Nunes, et al.. (2019). Pseudoprogression on PSMA PET imaging of a mCRPC patient under anti-PD1 treatment. European Journal of Nuclear Medicine and Molecular Imaging. 46(7). 1576–1577. 11 indexed citations
8.
Velho, Pedro Isaacsson, et al.. (2018). Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population. Journal of Global Oncology. 4(4). 1–10. 4 indexed citations
9.
Bastos, Diogo Assed, Carlos Dzik, Leopoldo Alves Ribeiro‐Filho, et al.. (2018). Tumor mutational burden (TMB), intratumoral genetic heterogeneity (ITGH) and BCG responsiveness in high-risk non-muscle invasive bladder cancer (NMIBC).. Journal of Clinical Oncology. 36(15_suppl). e16516–e16516. 1 indexed citations
10.
Chade, Daher C., Guilherme Garcia, Maurício Cordeiro, et al.. (2017). Effectiveness of the Moreau strain of Bacillus Calmette-Guerin (BCG) for nonmuscle invasive bladder cancer.. Journal of Clinical Oncology. 35(15_suppl). 4539–4539. 1 indexed citations
11.
Cordeiro, Maurício, Paulo Afonso Carvalho, Diogo Assed Bastos, et al.. (2017). Oncological outcomes of positive surgical margins in partial nephrectomy for renal cell carcinoma.. Journal of Clinical Oncology. 35(15_suppl). e16079–e16079. 1 indexed citations
12.
Maia, Manuel Caitano, et al.. (2017). Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Global Oncology. 4(4). 1–9. 12 indexed citations
13.
Dzik, Carlos & Sabrina T. Reis. (2015). Analysis of the Gene Expression of Renal Cell Carcinomas after Neoadjuvant Treatment with Sunitinib: An Exploratory DNA Microarray Study. Journal of Cancer Science & Therapy. 7(11). 1 indexed citations
14.
Barroso‐Sousa, Romualdo, et al.. (2014). Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Medical Oncology. 32(1). 443–443. 12 indexed citations
15.
Barroso‐Sousa, Romualdo, Rodrigo Ramella Munhoz, Milena Perez Mak, et al.. (2014). Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients. International braz j urol. 40(6). 835–841. 2 indexed citations
16.
Guindalini, Rodrigo Santa Cruz, et al.. (2013). Multiagent chemotherapy for metastatic adenocarcinoma of the seminal vesicle. Anti-Cancer Drugs. 25(1). 115–119. 4 indexed citations
17.
Moniz, Camila Motta Venchiarutti, et al.. (2013). Renal Medullary Carcinoma Response to Chemotherapy: a Referral Center Experience in Brazil. Rare Tumors. 5(3). 149–151. 21 indexed citations
18.
Stefani, Stephen, et al.. (2012). PCN61 Melody Brazil – Resource Use and Associated Costs With Metastatic Melanoma in Brazilian Health Care System. Value in Health. 15(7). A419–A420. 1 indexed citations
19.
Uno, Miyuki, Sueli Mieko Oba‐Shinjo, Carlos Clara, et al.. (2011). IDH1 mutations in a Brazilian series of Glioblastoma. Clinics. 66(1). 163–165. 22 indexed citations
20.
Leite, Kátia Ramos Moreira, et al.. (2000). Monoclonality of Asynchronous Bilateral Lymphoma of the Testis. European Urology. 38(6). 774–777. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bérengère Dadone‐Montaudié Breakdown of academic impact, for papers by Lukas Delasos Breakdown of academic impact, for papers by Benjamin Y. Tan Breakdown of academic impact, for papers by Emily S. Weg Breakdown of academic impact, for papers by Sonja Heibl Breakdown of academic impact, for papers by Vasiliki Michalarea Breakdown of academic impact, for papers by Marcelo Corassa Breakdown of academic impact, for papers by Walter Lindemann Breakdown of academic impact, for papers by Jason Mouabbi Breakdown of academic impact, for papers by Angad Singh
Rankless by CCL
2026